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Abstract 27 
Background: Lower muscle strength in midlife predicts disability and mortality in later life. 28 
Blood-borne factors, including growth differentiation factor 11 (GDF11), have been linked to 29 
muscle regeneration in animal models. We aimed to identify gene transcripts associated with 30 
muscle strength in adults. 31 
Methods: Meta-analysis of whole blood gene expression (overall 17,534 unique genes 32 
measured by microarray) and hand-grip strength in four independent cohorts (n=7,781, ages: 33 
20-104 years, weighted mean=56), adjusted for age, sex, height, weight, and leukocyte 34 
subtypes. Separate analyses were performed in subsets (older/younger than 60, 35 
male/female).  36 
Results: Expression levels of 221 genes were associated with strength after adjustment for 37 
cofactors and for multiple statistical testing, including ALAS2 (rate limiting enzyme in heme 38 
synthesis), PRF1 (perforin, a cytotoxic protein associated with inflammation), IGF1R and 39 
IGF2BP2 (both insulin like growth factor related). We identified statistical enrichment for 40 
hemoglobin biosynthesis, innate immune activation and the stress response. Ten genes 41 
were only associated in younger individuals, four in males only and one in females only. For 42 
example PIK3R2 (a negative regulator of PI3K/AKT growth pathway) was negatively 43 
associated with muscle strength in younger (<60 years) individuals but not older (>=60 44 
years). We also show that 115 genes (52%) have not previously been linked to muscle in 45 
NCBI PubMed abstracts 46 
Conclusions: This first large-scale transcriptome study of muscle strength in human adults 47 
confirmed associations with known pathways and provides new evidence for over half of the 48 
genes identified. There may be age and sex specific gene expression signatures in blood for 49 
muscle strength.   50 
 51 
 
 
3 
 
Introduction 52 
Muscle strength correlates with health and physical function, and poor muscle strength in 53 
midlife is a strong, independent predictor of health status decline and mortality over 25 years 54 
(40). Sufficient muscle strength in the hands, arms and legs is needed for everyday 55 
functioning; persons with poor strength are at high risk of disability, injury from falls, and 56 
other age-related morbidities (15, 25).  57 
Hand-grip is a frequently used summary measure of strength because it correlates well with 58 
strength of other key muscles and is relatively easy to measure with high precision; 59 
Bohannon et al. reported strong correlations between grip and knee extension strength 60 
(Pearson R=0.77 to 0.8) in a sample aged 18 to 85 years (7), with Samson et al. reporting 61 
similar estimates (43). Muscle strength (including grip strength) is a more important predictor 62 
of mortality risk than muscle mass (9, 32), and grip strength (but not muscle mass) was 63 
associated with poor physical functioning in older adults (51). The mechanisms underlying 64 
the association between lower strength and mortality are not entirely clear, but a recent 65 
large-scale multi-country follow-up study (n=142,861) reported that lower grip strength 66 
associated most strongly with cardiovascular mortality (28). Current theories emphasize the 67 
role of denervation not compensated by adequate re-innervation, mitochondrial dysfunction, 68 
cellular senescence, inflammation, changes in microenvironment, and local skeletal changes, 69 
among other factors (4, 44).  70 
Studies of heterochronic parabiosis (connecting the blood circulations of young and old mice) 71 
found that circulating factors, in particular lower GDF11 (growth and differentiation factor 11) 72 
in older mice, explained the lower muscle regenerative capacity in older compared to 73 
younger muscle (8, 11, 48). It is well established that circulating factors, such as pro-74 
inflammatory mediators and hormones (including testosterone), are strong correlates which 75 
predict the slope of decline of muscle mass and strength in aging humans (26). These blood 76 
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borne factors may function as systemic regulators influencing muscle and may be different 77 
from gene expression patterns in muscle itself.  78 
Previous studies of transcriptome associations with muscle strength in humans were 79 
conducted predominantly in muscle tissue, and are mostly limited by small sample size (30) 80 
or focus on candidate genes (34). These studies can be susceptible to false negatives 81 
statistical associations due to lack of power or coverage. A transcriptome-wide study of 82 
whole blood transcript associations with grip strength conducted by the InCHIANTI Aging 83 
Study (mean age 72 years, 71% ≥72 years old) found only one gene, CEBPB 84 
(CCAAT/enhancer-binding protein beta, required for macrophage-mediated muscle repair in 85 
a murine model (42)), to be associated with muscle strength in older humans after 86 
adjustment for confounders and multiple testing (18). A follow-up study in humans found that 87 
CEBPB expression increased following exercise-induced muscle damage (6). However, 88 
because of the limited sample size of both studies, important transcriptional signals may 89 
have been missed.  90 
In the present study we sought to test associations between transcripts expressed in whole 91 
blood and hand grip strength in multiple adult human cohorts. The majority of RNA in whole 92 
blood samples is derived from immature erythrocytes and platelets (~70% from reticulocytes 93 
and ~18% from reticulated platelets); however, these are predominantly globin-related and 94 
are not actively transcribed by circulating cells (1). The remaining  approximately 12% of 95 
RNA is from circulating white blood cells of all types, driving non-globin related gene 96 
expression. We have also performed subgroup analyses by age-group and gender, to check 97 
for heterogeneity in the results. We used a robust meta-analysis framework within four 98 
independent cohorts (n=7,781 participants) from the CHARGE (Cohorts for Heart and Aging 99 
Research in Genomic Epidemiology) consortium (37) to identify the genes whose levels of 100 
expression assessed by blood transcripts were associated with muscle strength.  101 
  102 
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Methods 103 
Study sample 104 
Characteristics of the cohorts are presented in Table 1. Complete data for the planned meta-105 
analysis were available for 7,781 participants from four cohorts; the Framingham Heart Study 106 
(23) (FHS, n=5,576, ages=24-90), the InCHIANTI study (13) (n=667, ages=30-104), the 107 
Rotterdam study (20) (RS, n=556, ages=46-89) and the Study of Health in Pomerania (52) 108 
(SHIP, n=982, ages=20-81) (total n=7,781). The FHS study included two related generations 109 
of participants (accounted for in the statistical methodology); the FHS Generation 2 (n=2,421, 110 
ages=40-90) and Generation 3 (n=3,155, ages=24-78) cohorts were included. The 111 
Netherlands Study of Depression and Anxiety (35) (NESDA, n=1,989, ages=18-65) is also 112 
reported, but was not included in the discovery meta-analysis due to unavailable data on 113 
white cell proportions necessary for the meta-analysis protocol. Overall the cohorts were 114 
quite similar with respect to sex-distribution and sampling methods, differing only by age 115 
distribution and lower mean hand-grip strength in the RS. Detailed study design and cohort 116 
information has been previously published (21). 117 
Four additional subset analyses were performed. The sub-samples available were 1) older 118 
participants ≥60 years (n=2,402), 2) younger participants <60 years (n=5,379), 3) male 119 
participants (n=3,557), 4) female participants (n=4,224).  120 
 121 
Phenotype 122 
The primary phenotype was hand-grip strength in kg (a normally distributed phenotype). In 123 
the FHS, hand grip strength was measured with a Jamar dynamometer with three trials 124 
performed in each hand, and the maximum of the six trials for each participant was used in 125 
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the analysis. In InCHIANTI each participant recorded their maximum grip strength three 126 
times in each hand, and the maximum recorded value of the six trials was used. In the 127 
Rotterdam Study grip strength of the non-dominant hand was measured three times for each 128 
participant, and the maximum recorded value was used. In the SHIP cohort participants were 129 
asked to press the hand dynamometer firmly for several seconds, once per hand (left and 130 
right), and the maximum value was used. Each participant in NESDA was measured twice 131 
with a Jamar dynamometer in their dominant hand, with the maximum recorded value used. 132 
 133 
Peripheral gene expression data 134 
Blood samples were drawn from participants and RNA was isolated, reverse-transcribed to 135 
cDNA, which was then amplified and hybridized to a microarray individually for each cohort; 136 
methods described in detail (21). Briefly, the FHS used Affymetrix Human Exon 1.0 ST 137 
GeneChips, characterizing the expression of 16,798 unique genes (after exclusion of 138 
probesets with relative log expression mean values <3). The InCHIANTI and SHIP studies 139 
used the Illumina HumanHT-12 v3 Expression BeadChip Kit, and the RS used the Illumina 140 
HumanHT-12 v4 Expression BeadChip Kit, with 37,348 probes measured on both Illumina 141 
platforms (22,911 unique genes; after exclusions of probes expressed above background in 142 
<5% of participants this becomes 15,639 unique genes). These four studies in the primary 143 
analysis all used PAXgene tubes to isolate and stabilize the RNA, thereby limiting the 144 
technical variability between studies. Finally the NESDA cohort utilized the Affymetrix Human 145 
Genome U219 Array, with expression information available on 18,212 unique gene 146 
identifiers. Quantile normalization and log2 transformation was performed on the gene 147 
expression data in each cohort, and both probes and samples were z-transformed. Raw data 148 
from gene expression profiling are available online (FHS [NCBI dbGAP: phs000363.v7.p8], 149 
InCHIANTI [GEO: GSE48152], NESDA [NCBI dbGAP: phs000486.v1.p1], RS [GEO: 150 
GSE33828] and SHIP-TREND [GEO: GSE36382]). 151 
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Systematically mapping pairs of probes to RefSeq transcripts (one Affymetrix Exon ST and 152 
one Illumina HumanHT-12 probe) found 26,746 probe-pairs corresponding to 17,534 unique 153 
RefSeq gene symbols. The assignment of a probe to one or more transcripts was performed 154 
as described previously (45). For the Illumina arrays, the transcript sequences derived from 155 
the 48,803 probe sequences provided in the Illumina annotation file (HumanHT-156 
12_V3_0_R3_11283641_A, version 3.0, 7/1/2010) were mapped against all available mRNA 157 
sequences provided in the UCSC genome annotation database (version 06/30/2013) using 158 
string matching. Altogether 29,818 probes were successfully mapped to one or more 159 
validated mRNAs. Probes that could neither be mapped to a unique mRNA nor to a single 160 
annotated RefSeq gene using the UCSC database were flagged accordingly in the 161 
annotation file. In total, 27,171 probes (55.7%) were unambiguously associated with a single 162 
mRNA or gene. The same method and version of the UCSC database was used for mapping 163 
the probes of the Affymetrix GeneChip Human Exon 1.0 ST microarray. For this array, probe 164 
sequences were obtained from the annotation file version HuEx-1_0-st-v2.r2 restricting the 165 
probes to the main probe types of the core dataset with unique cross hybridization type, and 166 
combining them at the level of transcript cluster. For this array system, 196,515 probes 167 
(86.0%) of 17,876 transcript clusters were unambiguously associated with a single mRNA or 168 
gene. Finally, the probes of both array systems were combined based on the same 169 
transcripts obtained from the mapping against the UCSC database.  170 
The Human Genome Nomenclature Committee (22) list 19,060 protein-coding genes (Sept 171 
15, 2014), less than the total “unique identifiers” mapped by the two arrays used in the 172 
overall meta-analysis; this discrepancy is due to probes on the array mapping to non-protein-173 
coding transcripts, which we have included under the term “unique genes” or “transcripts” in 174 
this manuscript. 175 
 176 
 177 
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 178 
Statistical analysis 179 
Using the R statistical software (39) and package “lme4” (3) each cohort performed a linear 180 
mixed effects model for each probe in their microarray data, using the probe as the outcome, 181 
muscle strength as an independent variable, and with the following covariates included as 182 
fixed effects; age, sex, height (cm), weight (kg), cell count estimates (neutrophils, monocytes, 183 
basophils and eosinophils), and fasting state (where applicable). By including these factors 184 
as covariates in the models our results are independent of inter-individual variation in, for 185 
example, lymphocyte cell counts. The following covariates were included as random effects; 186 
batch (e.g. amplification and/or hybridization), study site (in InCHIANTI), family structure (in 187 
FHS), and RNA quality (e.g. RNA Integrity Number - RIN - where available). Empirical cell 188 
counts were only available in half of the FHS cohort; the rest of the cohort was imputed using 189 
partial least square regression methods (see Online Methods for more details). 190 
 191 
Meta-analysis 192 
A sample-size weighted meta-analysis method was used, where an overall p-value and Z-193 
score for each probe are calculated which together describe the significance of the effect, 194 
and the direction and magnitude, respectively; this method was chosen over the effect 195 
size/standard error method because of the multiple array technologies and technical 196 
considerations that differed between the cohorts. The analysis was done using the Meta-197 
Analysis Tool for Genome Wide-Association Scans (METAL) (54) which took the effect size, 198 
sample size, and p-values from the individual cohort results as input (we set the “minor 199 
allele”, “major allele”, “minor allele frequency”, and “strand” to the same fixed value for all 200 
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cohorts and probes, as this package was developed for GWAS and these options are not 201 
relevant for gene expression data). 202 
For each analysis (the primary analysis including all individuals, and the four subset 203 
analyses) the Illumina-based cohorts (InCHIANTI, RS, SHIP) were meta-analyzed together, 204 
as these technologies are very similar, then a secondary meta-analysis was performed which 205 
used the FHS results and the Illumina results as the input; these are the final meta-analysis 206 
results reported. This reduced the heterogeneity in the meta-analysis due to array 207 
differences between the cohorts. 208 
Before interpretation of the results, probes were excluded if they were expressed in <5% of 209 
the sample or if the heterogeneity p-value calculated by METAL was <0.05. The Benjamini-210 
Hochberg (BH) (5) false-discovery rate (FDR) correction was applied to determine the 211 
statistically significant probes for each analysis. Validation was defined as a gene with 212 
p<0.05 in the NESDA cohort. 213 
 214 
Ontology enrichment and network analysis 215 
The WEB-based GEne SeT AnaLysis Toolkit (WebGestalt) online resource is a method for 216 
determining pathway enrichment (56). We conducted a “Gene Ontology” analysis (database 217 
version: Nov 11, 2012) and a “Human Phenotype Ontology” analysis (database version: May 218 
20, 2014), which uses a systematic approach to phenotype abnormalities to link them into 219 
ontologies (53). Default analysis options were selected, including BH multiple testing 220 
adjustment, and the list of 17,534 genes included in the meta-analysis we used as the 221 
“background”. 222 
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A co-expression analysis was performed in the FHS (as the study with the largest sample 223 
size) where Spearman correlations were determined between each gene significantly 224 
associated with muscle strength, and all other genes (after adjusting the data for the 225 
covariates mentioned in the Statistical Analysis methods section). Genes correlated with rho 226 
≥ 0.5 were selected for visualization in Cytoscape (v3.2.1). Ontology enrichment of networks 227 
was performed in Cytoscape using the BiNGO plugin (v2.44). 228 
 229 
A priori genes associated with muscle function 230 
We selected sets of genes known to influence muscle function for a priori analysis to 231 
highlight whether the pathways in muscle tissue are also important in whole blood. Kelch 232 
proteins, including KLHL19, KLHL31, KLHL39m, and KLHDC1, are involved in skeletal 233 
muscle function and development [8]; canonical and non-canonical Wnt signaling play crucial 234 
roles in maintenance and development of skeletal muscle [7]; insulin-like growth factors 235 
(IGF’s) are also known to play roles in muscle growth and homeostasis [9], and finally TGF-β 236 
family members, including myostatin (GDF8) (27) and GDF11. Supplementation of GDF11 in 237 
mice was reported to ameliorate the sarcopenia-like phenotype [15]. In their 2007 study, 238 
Melov et al identified 586 unique genes expressed in muscle that were associated with 239 
endurance exercise training and differed between older and younger men (30), which we 240 
also checked for associations with muscle strength in this analysis. 241 
 242 
Systematic literature search for genes 243 
For each significant gene in the analysis a systematic search of literature was performed by 244 
accessing the “publications” list from GeneCards (www.genecards.org) (41), which has the 245 
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advantage of including publications where the gene ID may have changed over time. From 246 
this list the title and abstract were downloaded from NCBI PubMed 247 
(www.ncbi.nlm.nih.gov/pubmed). Searches were then made within each publication for the 248 
text string “muscle”, and results counted. 249 
  250 
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Results 251 
Meta-analysis: genes associated with muscle strength 252 
Overall, 26,746 probe-pairs (corresponding probes on the Affymetrix and Illumina platforms), 253 
mapping to 17,534 unique gene identifiers, were available for the meta-analysis. Including 254 
data from all 7,781 participants, 208 unique genes (246 probe-pairs) were associated with 255 
muscle strength (FDR<0.05; Figure 1; see Supplementary Table 1 for all significant results) 256 
after correction for multiple confounders, and excluding results with significant heterogeneity 257 
(het p<0.05) between cohorts; 133 were negatively associated with grip strength, 75 were 258 
positively associated.  259 
Of the 208 unique genes associated with muscle strength in the meta-analysis all were 260 
significant in FHS alone (nominal p<0.05), and 79 (38%) were also “independently” 261 
associated with muscle strength in the Illumina meta-analysis (nominally significant; p<0.05). 262 
Details of the statistically most significant ‘top’ 20 transcripts are shown in Table 2. The 263 
proportion “independently replicated” was greater for the top 30 most significant genes 264 
identified in the meta-analysis (21 of 30 = 70%).  265 
 266 
Meta-analysis in subsets of the participants 267 
The analyses in subsets of the participants identified 13 genes associated with muscle 268 
strength at transcriptome-wide significance in the meta-analysis that were not identified in the 269 
analysis of all participants together (Table 3; see Supplementary Table 2-4 for full results 270 
for each subset). We also investigated whether the 208 genes identified in the analysis of all 271 
individuals were nominally significant (p<0.05) in the subsets. 153 of the 208 genes were 272 
nominally significant in the older participants, 198 in the younger, 200 in the males and 121 273 
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in the females (Supplementary Table 1). Supplementary Table 5 includes additional 274 
information for all genes included in Tables 2 & 3. 275 
 276 
Significant genes only available on one array 277 
Due to differences between the array technologies and relative abundance of transcripts, not 278 
all the genes were eligible for the meta-analysis. In the analysis on all individuals, 1,123 279 
probes (898 unique identifiers) were present on the Affymetrix Exon array that did not have a 280 
corresponding probe on the Illumina array; 21 of these probes were significantly associated 281 
with hand-grip strength after BH adjustment for multiple testing (see Table 4 for top 20 282 
probes in the “all individuals” analysis and Supplementary Tables 6-8 for list of significant 283 
probes in each of the FHS analyses with significant results).  In the Illumina array, 7,768 284 
probes (6,119 unique gene identifiers) were available that did not map to a gene/transcript in 285 
the Affymetrix Exon array (after excluding lowly expressed probes). None of the probes were 286 
significantly associated with muscle strength after BH multiple testing correction. 287 
 288 
Ontology enrichment of strength-associated genes 289 
Two analyses were performed to identify pathways using the WebGestalt web resource 290 
based on the 208 genes associated with muscle strength in the meta-analysis of all 291 
participants; 292 
1. Gene Ontology analysis found that 10 biological processes were significantly enriched 293 
(FDR<0.05) (Table 5) including “hemoglobin metabolic process” and related processes, 294 
“innate immune response” (18 genes) and the stress response (55 genes); 10 molecular 295 
functions were enriched (including “protein binding genes”), and 10 cellular component 296 
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pathways were enriched (including “intracellular membrane-bound organelle”) (See 297 
Supplementary Table 9).  298 
2. Human Phenotype Ontology analysis found 10 phenotypes significantly enriched in the 299 
genes, including “Anemia due to reduced life span of red cells”, “Hemolytic Anemia”, and 300 
“Abnormality of erythrocytes” (See Supplementary Table 10). 301 
Additionally, network analysis in the FHS of all genes correlated (rho ≥ 0.5) with the strength-302 
associated genes (n=425) revealed four clusters with at least 10 genes, all of which had a 303 
number of significantly (FDR p<0.05) enriched pathways (Supplementary Table 11): 1) the 304 
largest cluster (n=333 of 425 genes) included “protein ubiquitination”, “erythrocyte 305 
homeostasis”, and “cellular metabolic process”. 2) The second cluster (n=32 genes) was 306 
enriched for genes in “regulation of cell communication”, “actin cytoskeleton” and “ATP 307 
metabolic process”. 3) The third cluster (n=18) had two enriched ontologies only: “cell 308 
surface receptor-linked signaling pathway” and “cytolysis”. 4) The final cluster (n=10) was 309 
enriched for terms including “negative regulator or immune system process” and “negative 310 
regulation of complement activation”. 311 
 312 
A priori genes associated with muscle function 313 
Of 20 IGF-related genes tested in this meta-analysis two were significantly associated with 314 
muscle strength: IGF1R (positively associated) and IGF2BP2 (negatively associated; meta-315 
analysis FDR=3.2x10-2 and FDR=1.2x10-3, respectively). Expression of myostation (MSTN), 316 
follistatin (FST) and GDF11 were not associated with muscle strength (FDR>0.05). 40 unique 317 
Kelch genes were tested in the meta-analysis; none were associated with muscle strength in 318 
whole blood (FDR>0.05). 18 unique Wnt genes (from WNT1 to WNT9B) were tested in the 319 
meta-analysis; none were associated with muscle strength in whole blood (FDR>0.05). All 10 320 
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Frizzled genes (FZD1-10, receptors for the Wnt pathway) were also available to test; none 321 
were associated with muscle strength. Similarly all three Dishevelled genes were available to 322 
test (DVL1-3, acts directly downstream of the Frizzled receptors) and none were associated 323 
with muscle strength. Of 586 genes identified by Melov et al that were differentially 324 
expressed in muscle tissue between old and young men following endurance training (30) 325 
four were associated with muscle strength in this analysis: ANP32B, CIRBP, MCM7 and 326 
MGST1. 327 
 328 
 329 
Most associated genes are not previously linked to muscle in the literature 330 
For each of the 221 genes associated with muscle strength we searched in the published 331 
literature cataloged on GeneCards and NCBI Pubmed titles and abstracts, using the search 332 
term “muscle”: for 115 of these 221 genes (52%) there were no mentions of muscle (as of 333 
Nov 12, 2014; Supplementary Table 12). 334 
 335 
Few genes replicate in the NESDA cohort 336 
NESDA was not included in the meta-analysis due to data limitations: the lack of empirically 337 
determined or reliably imputed white cell count data, the use of a different microarray 338 
technology (a predecessor to the Exon array used by FHS, much more dissimilar than the 339 
v3/v4 Illumina arrays are to one another), and a younger population than the other cohorts 340 
included in the meta-analysis (max age=65, see Table 1). 341 
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As noted above, in total 221 unique genes were associated with muscle strength across all 342 
the meta-analyses performed. Of 208 genes significantly associated with muscle strength in 343 
analysis 1 (all participants) it was possible to test 144 in the NESDA cohort; 7 genes were 344 
also associated with muscle strength (p<0.05) in the NESDA cohort (ACSL6, ALDH5A1, 345 
CARHSP1, FGL1, NRG1, PIGB, SIGLEC7).  346 
 347 
Associations with knee strength 348 
Maximum knee and grip strength (both in Kg) were measured in 619 participants in the 349 
InCHIANTI study and were highly correlated (Pearson R=0.751), and were significantly 350 
associated after adjustment for age, sex, height and weight (coefficient=0.193, p=8.2x10-15) 351 
in linear regression models with knee strength as the dependent variable. 352 
 353 
  354 
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Discussion 355 
In this discovery study we set out to determine whether specific transcript levels in blood are 356 
associated with muscle strength in multiple human cohorts including mostly middle-aged 357 
volunteers. Previous cross-sectional (and longitudinal) studies have shown that the degree 358 
and rate of loss of strength (and muscle mass) is greater in older participants (31). We 359 
therefore performed stratified analyses by age and gender to determine whether transcripts 360 
or pathways associated with muscle strength in whole blood differ between these groups. 361 
208 unique genes were associated with muscle strength in the analysis of all participants 362 
(Table 2 for 20 most robust associations). Thirteen additional unique genes were identified 363 
that were only associated when participants were separated into older/younger or 364 
male/female groups (Table 3). In total 221 unique genes were associated with muscle 365 
strength in at least one analysis, 52% of which were not previously linked to the term 366 
“muscle” in the published literature cataloged on GeneCards and PubMed (as of Nov 12, 367 
2014). 368 
We observe significant associations between muscle strength and expression of IGF1R and 369 
IGF2BP2 (positive and negative directions of association with muscle, respectively), growth 370 
factors involved in skeletal muscle growth (33, 46); the former is known to enhance cell 371 
survival by mediating IGF1 signaling, and the latter modulates IGF2 translation and has 372 
genetic variants associated with type-2 diabetes (19). Of 586 genes that differ in expression 373 
in muscle between old and young men after endurance training (30), four were associated 374 
with grip strength in this study: MGST1 (negative direction), an immune mediator which may 375 
protect against oxidative stress (49); MCM7 (positive direction), which regulates DNA 376 
replication during proliferation (12); CIRBP (positive direction), which promotes inflammation 377 
in response to shock and sepsis (38); and ANP32B (negative direction), a cell-cycle 378 
progression and anti-apoptosis factor (41). These latter results suggest that most blood 379 
based gene expression associated with strength is different from that seen in muscle itself, 380 
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which is not unexpected given the respective systemic regulatory versus myofibril 381 
maintenance functions involved. Further work should explore whether transcripts that alter in 382 
response to exercise show overlaps between circulating cells and muscle. Interestingly, no 383 
genes from the Wnt or Kelch pathways (both known to be important for muscle function (14, 384 
29)) were associated with strength in this analysis; nor was GDF11, a protein that can 385 
reverse age-related muscle dysfunction in mice (48), although as noted we observe 386 
associations between strength and expression of two IGF-related genes. 387 
Other genes of note include CCR6 and PRF1 (both positively associated with muscle 388 
strength and age (17)): CCR6 is implicated in B-cell maturation and recruitment (36); perforin 389 
(PRF1) is a protein secreted by cytotoxic T-cells which creates pores in membranes to permit 390 
apoptosis-inducing granzyme into the target cell (50). These findings are consistent with the 391 
notion that inflammation may be associated with muscle repair, maintenance and turnover, at 392 
least in part by interfering with the production and biological activity of IGF-1 (2). 393 
NANOG expression was measured in the FHS analysis only and is positively associated with 394 
strength in the FHS analysis (Table 4); NANOG can reverse aging of some stem cells (16) 395 
and, in combination with three other genes (OCT4, SOX2, and LIN28, not significant in this 396 
analysis), can induce pluripotency of somatic cells (55). This may suggest that differentiation 397 
(of whole blood cells) is inversely correlated with muscle strength, but the mechanisms are 398 
unclear. 399 
 400 
Genes identified in subset analyses 401 
Thirteen genes were associated with muscle strength at transcriptome-wide significance in 402 
the subset analysis only (Table 3). These were predominantly in the younger (<60 years) 403 
group and included PIK3R2, a negative regulator of the PI3K/AKT growth pathway; the 404 
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negative expression association with strength suggests that there is increased PI3K activity 405 
(due to reduced expression of PIK3R2) with increasing muscle strength, in whole blood. This 406 
association is observed in the younger subset (p=6x10-5) but not in the older subset, even 407 
nominally (p=0.92), suggesting differences in growth pathway expression in blood with 408 
respect to muscle strength as individuals age. Similarly expression of PDK4 (inhibits 409 
pyruvate dehydrogenase in mitochondria, thereby reducing the conversion of pyruvate into 410 
acetyl-CoA) is negatively associated with strength, suggesting increased pyruvate 411 
dehydrogenase activity with increased strength in younger individuals only. PKN2, 412 
(associated with height (19) and cell-cycle progression), is positively associated with strength 413 
in the younger individuals, underlining the difference in growth pathways in whole blood 414 
between younger and older individuals. See Supplementary Table 5 for more details on the 415 
other results. 416 
Defensin, Alpha 4, Corticostatin (DEFA4, negative strength association in the analysis of 417 
females only) is a cytotoxic peptide that has antimicrobial activity against Gram-negative 418 
bacteria (predominantly) (36). In males, expression of RAC1 (membrane-associated GTPase 419 
involved in signal transduction, including growth signals) and NDUFS1 (member of 420 
mitochondrial complex 1, may form part of the active site) were positively associated with 421 
muscle strength; these associations may suggest that on average males have specific 422 
energy and growth-related gene expression relating to strength. 423 
No genes were associated (transcriptome-wide) in the older participants only; although the 424 
sample size was still reasonably high (2,402 participants), variability in the strength 425 
phenotype as individuals age and development of various co-morbidities plus chronic 426 
inflammation may reduce the power to detect associations. Subset-specific gene-expression 427 
associations with strength reported here need to be replicated and added to, as we may lack 428 
statistical power in this study to detect smaller-effect associations, and the microarrays do 429 
not quantify all transcripts or isoforms present. 430 
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 431 
Enrichment analysis 432 
WebGestalt analyses identified statistically significant enrichment for genes in the biological 433 
process “Hemoglobin Metabolic Process” and the phenotypic abnormality “Hemolytic 434 
Anemia”, amongst others. Anemia is a cross-sectional correlate of muscle strength and 435 
predicts accelerated muscle strength decline with aging (10), while hemoglobin levels are 436 
positively associated with muscle strength and density (10). Circulating reticulocytes 437 
(erythrocyte precursors with some residual RNA present) were not adjusted for in this 438 
analysis and are likely the source of the associations with genes such as ALAS2 (strongest 439 
meta-analysis association, negative direction - a rate-limiting step in heme biosynthesis (24)).  440 
“Innate Immune Response” - which includes macrophages - genes were also enriched in the 441 
results. CEBPB, the gene implicated in the macrophage wound-healing response (42) and 442 
significantly associated with muscle strength in the 2012 study by InCHIANTI (18), did not 443 
replicate in the other cohorts. This could be due to methodological differences between the 444 
previous study and this meta-analysis, as well as differences in age distribution (81% of the 445 
InCHIANTI cohort is aged >=60 years, compared to 31% in this analysis, which includes the 446 
InCHIANTI cohort; Table 1). The implications are unclear given the mouse model evidence 447 
of plausible biological mechanism (42) and evidence in humans that exercise-induced 448 
muscle damage is associated with CEBPB expression changes in whole blood (6). Further 449 
work is required in older and frail groups. 450 
Co-expression analysis of all genes correlated with those identified in the meta-analysis to be 451 
significantly associated with strength revealed four clusters. Ontology enrichment analysis of 452 
these revealed very similar results to those identified using WebGestalt only on the genes 453 
significantly associated with strength, emphasizing the association of immune activation and 454 
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cell signaling pathways to muscle strength in whole blood, in addition to hemoglobin 455 
pathways. 456 
 457 
Limitations  458 
There are several potential limitations of this study including its cross-sectional design; it is 459 
not possible to determine a causal direction in this study for the associations reported, but 460 
the robustly identified markers emerging provide a sound foundation for follow-up studies to 461 
address causation. Grip strength is strongly correlated with strength in other key muscle 462 
systems (see introduction), but further work will be needed to confirm more specific gene 463 
expression associations with strength in other muscle groups. Grip strength can be 464 
influenced by non-muscle strength factors, including functional anomalies in the hands, for 465 
example caused by Rheumatoid Arthritis (47), and work is needed to clarify whether any of 466 
our findings reflect these alternative influences.  467 
Another potential limitation is the mixed cell subtype composition of “whole blood”: our 468 
analysis approach based on overall expression should have greater power to detect net 469 
expression changes in common immune cell types or large changes in expression of highly 470 
specific genes, but will have less power to detect smaller expression changes within less 471 
numerous cell subtypes. The cell subtype origins of the top transcripts reported here now 472 
need to be identified. Additionally, the microarray technology used across the participating 473 
cohorts was not the same. However, 21 (70%) of the top 30 meta-analysis results were 474 
independently replicated between the platforms, which suggests that the top (most strongly 475 
associated) results are very robust to cohort and array differences. Also, the current analysis 476 
has identified expressed genes statistically associated with muscle strength, but future work 477 
will be needed to identify the mechanisms underlying these associations, and whether these 478 
act on muscle directly or through indirect pathways, perhaps with effects on central 479 
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command, cerebellar coordination or neural transmission. Finally, work is needed on whether 480 
the identified strength associated gene expression transcripts are predictive of subsequent 481 
changes in strength or functional decline.  482 
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Conclusions 483 
In this first large-scale transcriptome wide study in human blood, we have identified robust 484 
associations between the expression of 221 genes and muscle strength in adults. Several 485 
known pathways were confirmed, including growth factor-related genes, the innate immune 486 
response and hemoglobin metabolism. For 115 genes this analysis appears to provide the 487 
first published link to muscle. The analysis also suggests that parts of the expression 488 
signatures may be specific to subgroups, notably with 10 genes associated with muscle 489 
strength only in younger people.  490 
Further work is needed to establish which of the identified genes predict future changes in 491 
strength. The findings of genes via expression microarrays may help identify key changes in 492 
cell subtypes in blood contributing to strength, through studies of the cellular origins of gene 493 
expression signals. Future research should also include longitudinal data to assess whether 494 
expression of the identified genes predicts poor muscle strength or functional outcomes. 495 
 496 
 497 
  498 
 
 
24 
 
List of Abbreviations 499 
 500 
BH Benjamini-Hochberg 
cDNA Complementary DNA (usually from PCR, can be originally DNA or RNA) 
CHARGE Cohorts for Heart and Aging Research in Genomic Epidemiology 
DNA Deoxyribonucleic Acid 
FDR False-Discovery Rate 
FHS Framingham Heart Study 
GWAS Genome-Wide Association Study 
IL6 Interleukin 6 
InCHIANTI Invecchiare Nel Chianti – aging in the Chianti region of Italy 
METAL Meta-Analysis Tool for Genome Wide-Association Scans 
NESDA Netherlands Study of Depression and Anxiety 
QC Quality Control 
RIN RNA Integrity Number 
RNA Ribonucleic Acid 
RS Rotterdam Study 
SHIP Study of Health in Pomerania 
WebGestalt WEB-based GEne SeT AnaLysis Toolkit 
 501 
  502 
 
 
25 
 
Disclosures 503 
The authors declare that they have no competing interests. 504 
  505 
 
 
26 
 
Authors’ Contributions 506 
LCP participated in the design of analysis, performed analysis of the InCHIANTI data, 507 
performed the meta-analysis, interpreted the results and co-wrote the manuscript. RJ, TK, 508 
MJP and RJ2 participated in design of analysis, performed analysis in their respective 509 
cohorts, provided interpretation of results and contributed to draft manuscripts. DK, DPK and 510 
LWH had substantial contributions to study design and results interpretation. AT performed 511 
microarray re-annotation by sequence mapping. JEP provided methods input and comments 512 
to manuscript. DL, HL, KL, PJM, SB, WEH, DGH, ABS, TT, GG, AH, AGU, RB, SG, GH, CM 513 
and UV were involved in data acquisition and methods development, including designing this 514 
analysis. BWJHP, JBJM, LF, TK2 and JMM contributed to the analysis plan and methods 515 
discussion, provided interpretation of results and contributed to draft manuscripts, and 516 
oversaw analyses performed within their cohorts. DM participated in the design of the 517 
analysis, interpreted the results and co-wrote the manuscript. All authors read, provided 518 
comments, and approved the final manuscript. 519 
  520 
 
 
27 
 
Funding and Acknowledgements 521 
FHS gene expression profiling was funded through the Division of Intramural Research 522 
(Principal Investigator, Daniel Levy), National Heart, Lung, and Blood Institute, National 523 
Institutes of Health, Bethesda, MD. Dr. Murabito is supported by NIH grant R01AG029451.  524 
Dr. Kiel is supported by NIH R01 AR41398. The Framingham Heart Study is supported by 525 
National Heart, Lung, and Blood Institute contract N01-HC-25195. 526 
The InCHIANTI study was supported in part by the Intramural Research Program, National 527 
Institute on Aging, NIH, Baltimore MD USA. D.M. and L.W.H. were generously supported by 528 
a Wellcome Trust Institutional Strategic Support Award (WT097835MF). W.E.H. was funded 529 
by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied 530 
Health Research and Care (CLAHRC) for the South West Peninsula. The views expressed in 531 
this publication are those of the authors and not necessarily those of the NHS, the NIHR or 532 
the Department of Health in England. 533 
The infrastructure for the NESDA study (www.nesda.nl) is funded through the Geestkracht 534 
program of the Netherlands Organisation for Health Research and Development (Zon-Mw, 535 
grant number 10-000-1002) and is supported by participating universities and mental health 536 
care organizations (VU University Medical Center, GGZ inGeest, Arkin, Leiden University 537 
Medical Center, GGZ Rivierduinen, University Medical Center Groningen, Lentis, GGZ 538 
Friesland, GGZ Drenthe, Scientific Institute for Quality of Healthcare (IQ healthcare), 539 
Netherlands Institute for Health Services Research (NIVEL) and Netherlands Institute of 540 
Mental Health and Addiction (Trimbos Institute). 541 
The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, 542 
Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), 543 
the Netherlands Organisation of Scientific Research NWO Investments (nr. 544 
175.010.2005.011, 911-03-012), the Research Institute for Diseases in the Elderly (014-93-545 
 
 
28 
 
015; RIDE2), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare 546 
and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The 547 
authors are grateful to the study participants, the staff from the Rotterdam Study and the 548 
participating general practitioners and pharmacists. The generation and management of 549 
RNA-expression array data for the Rotterdam Study was executed and funded by the Human 550 
Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, 551 
Erasmus MC, the Netherlands. We thank Marjolein Peters, MSc, Ms. Mila Jhamai, Ms. 552 
Jeannette M. Vergeer-Drop, Ms. Bernadette van Ast-Copier, Mr. Marijn Verkerk and Jeroen 553 
van Rooij, BSc for their help in creating the RNA array expression database. 554 
SHIP is part of the Community Medicine Research net of the University of Greifswald, 555 
Germany, which is funded by the Federal Ministry of Education and Research (grants no. 556 
01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social 557 
Ministry of the Federal State of Mecklenburg-West Pomerania, and the network ‘Greifswald 558 
Approach to Individualized Medicine (GANI_MED)’ funded by the Federal Ministry of 559 
Education and Research (grant 03IS2061A). The University of Greifswald is a member of the 560 
'Center of Knowledge Interchange' program of the Siemens AG and the Caché Campus 561 
program of the InterSystems GmbH. 562 
  563 
 
 
29 
 
References 564 
1.  Affymetrix. Technical Note: Factors Affecting Blood Gene Expression [Online]. 2011. 565 
http://www.panomics.com/downloads/QG_BloodGene_TN_RevB_110719.pdf. 566 
2.  Barbieri M, Ferrucci L, Ragno E, Corsi A, Bandinelli S, Bonafè M, Olivieri F, 567 
Giovagnetti S, Franceschi C, Guralnik JM, Paolisso G. Chronic inflammation and 568 
the effect of IGF-I on muscle strength and power in older persons. Am J Physiol 569 
Endocrinol Metab 284: E481–E487, 2003. 570 
3.  Bates D, Mächler M, Bolker B. Fitting linear mixed-effects models using lme4. J Stat 571 
Softw … submitted: 51, 2012. 572 
4.  Baylis D, Ntani G, Edwards MH, Syddall HE, Bartlett DB, Dennison EM, Martin-573 
Ruiz C, von Zglinicki T, Kuh D, Lord JM, Aihie Sayer A, Cooper C. Inflammation, 574 
Telomere Length, and Grip Strength: A 10-year Longitudinal Study. Calcif Tissue Int 575 
95: 54–63, 2014. 576 
5.  Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and 577 
powerful approach to multiple testing. J. R. Stat. Soc. Ser. B. . 578 
6.  Blackwell J, Harries LW, Pilling LC, Ferrucci L, Jones A, Melzer D. Changes in 579 
CEBPB expression in circulating leukocytes following eccentric elbow-flexion exercise. 580 
J. Physiol. Sci. ( November 13, 2014). doi: 10.1007/s12576-014-0350-7. 581 
7.  Bohannon RW, Magasi SR, Bubela DJ, Wang YC, Gershon RC. Grip and Knee 582 
extension muscle strength reflect a common construct among adults. Muscle and 583 
Nerve 46: 555–558, 2012. 584 
8.  Carlson B, Faulkner J. Muscle transplantation between young and old rats: age of 585 
host determines recovery. Am J Physiol Physiol 256: C1262, 1989. 586 
9.  Cesari M, Pahor M, Lauretani F, Zamboni V, Bandinelli S, Bernabei R, Guralnik 587 
JM, Ferrucci L. Skeletal muscle and mortality results from the InCHIANTI Study. J 588 
Gerontol A Biol Sci Med Sci 64: 377–84, 2009. 589 
10.  Cesari M, Penninx BWJH, Lauretani F, Russo CR, Carter C, Bandinelli S, 590 
Atkinson H, Onder G, Pahor M, Ferrucci L. Hemoglobin levels and skeletal muscle: 591 
results from the InCHIANTI study. J Gerontol A Biol Sci Med Sci 59: 249–54, 2004. 592 
11.  Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA. 593 
Rejuvenation of aged progenitor cells by exposure to a young systemic environment. 594 
Nature 433: 760–4, 2005. 595 
12.  Cortez D, Glick G, Elledge SJ. Minichromosome maintenance proteins are direct 596 
targets of the ATM and ATR checkpoint kinases. Proc Natl Acad Sci U S A 101: 597 
10078–83, 2004. 598 
13.  Ferrucci L, Bandinelli S, Benvenuti E, Di Iorio A, Macchi C, Harris TB, Guralnik 599 
JM. Subsystems contributing to the decline in ability to walk: bridging the gap between 600 
epidemiology and geriatric practice in the InCHIANTI study. J Am Geriatr Soc 48: 601 
1618–25, 2000. 602 
 
 
30 
 
14.  Gupta VA, Beggs AH. Kelch proteins: emerging roles in skeletal muscle development 603 
and diseases. Skelet Muscle 4: 11, 2014. 604 
15.  Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity 605 
function in persons over the age of 70 years as a predictor of subsequent disability. N 606 
Engl J Med 332: 556–61, 1995. 607 
16.  Han J, Mistriotis P, Lei P, Wang D, Liu S, Andreadis ST. Nanog reverses the 608 
effects of organismal aging on mesenchymal stem cell proliferation and myogenic 609 
differentiation potential. Stem Cells 30: 2746–59, 2012. 610 
17.  Harries LW, Hernandez D, Henley W, Wood AR, Holly AC, Bradley-Smith RM, 611 
Yaghootkar H, Dutta A, Murray A, Frayling TM, Guralnik JM, Bandinelli S, 612 
Singleton A, Ferrucci L, Melzer D. Human aging is characterized by focused 613 
changes in gene expression and deregulation of alternative splicing. Aging Cell 10: 614 
868–78, 2011. 615 
18.  Harries LW, Pilling LC, Hernandez LDG, Bradley-Smith R, Henley W, Singleton 616 
AB, Guralnik JM, Bandinelli S, Ferrucci L, Melzer D. CCAAT-enhancer-binding 617 
protein-beta expression in vivo is associated with muscle strength. Aging Cell 11: 262–618 
268, 2012. 619 
19.  Hindorff L, MacArthur J, Wise A, Junkins H, Hall P, Klemm A, Manolio T. A 620 
Catalog of Published Genome-Wide Association Studies [Online]. [date unknown]. 621 
www.genome.gov/gwastudies. 622 
20.  Hofman A, van Duijn CM, Franco OH, Ikram MA, Janssen HLA, Klaver CCW, 623 
Kuipers EJ, Nijsten TEC, Stricker BHC, Tiemeier H, Uitterlinden AG, Vernooij 624 
MW, Witteman JCM. The Rotterdam Study: 2012 objectives and design update. Eur J 625 
Epidemiol 26: 657–86, 2011. 626 
21.  Huan T, Esko T, Peters MJ, Pilling LC, Schramm K, Schurmann C, Chen BH, Liu 627 
C, Joehanes R, Johnson AD, Yao C, Ying S, Courchesne P, Milani L, 628 
Raghavachari N, Wang R, Liu P, Reinmaa E, Dehghan A, Hofman A, Uitterlinden 629 
AG, Hernandez DG, Bandinelli S, Singleton A, Melzer D, Metspalu A, Carstensen 630 
M, Grallert H, Herder C, Meitinger T, Peters A, Roden M, Waldenberger M, Dörr 631 
M, Felix SB, Zeller T, Vasan R, O’Donnell CJ, Munson PJ, Yang X, Prokisch H, 632 
Völker U, van Meurs JBJ, Ferrucci L, Levy D. A Meta-analysis of Gene Expression 633 
Signatures of Blood Pressure and Hypertension. PLOS Genet 11: e1005035, 2015. 634 
22.  HUGO Gene Nomenclature Committee. HGNC [Online]. [date unknown]. 635 
http://www.genenames.org/. 636 
23.  Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation 637 
of coronary heart disease in families. The Framingham offspring study. Am J 638 
Epidemiol 110: 281–90, 1979. 639 
24.  Khan AA, Quigley JG. Control of intracellular heme levels: heme transporters and 640 
heme oxygenases. Biochim Biophys Acta 1813: 668–82, 2011. 641 
25.  Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR, Harris TB. Sarcopenia: 642 
etiology, clinical consequences, intervention, and assessment. Osteoporos Int 21: 643 
543–59, 2010. 644 
 
 
31 
 
26.  Lee CE, McArdle A, Griffiths RD. The role of hormones, cytokines and heat shock 645 
proteins during age-related muscle loss. Clin Nutr 26: 524–34, 2007. 646 
27.  Lee S-J, Lee Y-S, Zimmers TA, Soleimani A, Matzuk MM, Tsuchida K, Cohn RD, 647 
Barton ER. Regulation of Muscle Mass by Follistatin and Activins. Mol Endocrinol 24: 648 
1998–2008, 2010. 649 
28.  Leong DP, Teo KK, Rangarajan S, Lopez-Jaramillo P, Avezum A, Orlandini A, 650 
Seron P, Ahmed SH, Rosengren A, Kelishadi R, Rahman O, Swaminathan S, 651 
Iqbal R, Gupta R, Lear SA, Oguz A, Yusoff K, Zatonska K, Chifamba J, Igumbor 652 
E, Mohan V, Anjana RM, Gu H, Li W, Yusuf S, Prospective Urban Rural 653 
Epidemiology (PURE) Study investigators. Prognostic value of grip strength: 654 
findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet (2015). 655 
doi: 10.1016/S0140-6736(14)62000-6. 656 
29.  Von Maltzahn J, Chang NC, Bentzinger CF, Rudnicki MA. Wnt signaling in 657 
myogenesis. Trends Cell Biol 22: 602–9, 2012. 658 
30.  Melov S, Tarnopolsky M a, Beckman K, Felkey K, Hubbard A. Resistance exercise 659 
reverses aging in human skeletal muscle. PLoS One 2: e465, 2007. 660 
31.  Mitchell WK, Williams J, Atherton P, Larvin M, Lund J, Narici M. Sarcopenia, 661 
dynapenia, and the impact of advancing age on human skeletal muscle size and 662 
strength; a quantitative review. Front Physiol 3: 260, 2012. 663 
32.  Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky 664 
SB, Tylavsky FA, Rubin SM, Harris TB. Strength, but not muscle mass, is 665 
associated with mortality in the health, aging and body composition study cohort. J 666 
Gerontol A Biol Sci Med Sci 61: 72–77, 2006. 667 
33.  Paoni NF, Peale F, Wang F, Errett-Baroncini C, Steinmetz H, Toy K, Bai W, 668 
Williams PM, Bunting S, Gerritsen ME, Powell-Braxton L. Time course of skeletal 669 
muscle repair and gene expression following acute hind limb ischemia in mice. Physiol 670 
Genomics 11: 263–272, 2002. 671 
34.  Patel HP, Al-Shanti N, Davies LC, Barton SJ, Grounds MD, Tellam RL, Stewart 672 
CE, Cooper C, Sayer AA. Lean Mass, Muscle Strength and Gene Expression in 673 
Community Dwelling Older Men: Findings from the Hertfordshire Sarcopenia Study 674 
(HSS). Calcif. Tissue Int. ( July 24, 2014). doi: 10.1007/s00223-014-9894-z. 675 
35.  Penninx BWJH, Beekman ATF, Smit JH, Zitman FG, Nolen WA, Spinhoven P, 676 
Cuijpers P, De Jong PJ, Van Marwijk HWJ, Assendelft WJJ, Van Der Meer K, 677 
Verhaak P, Wensing M, De Graaf R, Hoogendijk WJ, Ormel J, Van Dyck R. The 678 
Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and 679 
methods. Int J Methods Psychiatr Res 17: 121–40, 2008. 680 
36.  Pruitt KD, Brown GR, Hiatt SM, Thibaud-Nissen F, Astashyn A, Ermolaeva O, 681 
Farrell CM, Hart J, Landrum MJ, McGarvey KM, Murphy MR, O’Leary NA, Pujar S, 682 
Rajput B, Rangwala SH, Riddick LD, Shkeda A, Sun H, Tamez P, Tully RE, Wallin 683 
C, Webb D, Weber J, Wu W, DiCuccio M, Kitts P, Maglott DR, Murphy TD, Ostell 684 
JM. RefSeq: an update on mammalian reference sequences. Nucleic Acids Res 42: 685 
D756–63, 2014. 686 
 
 
32 
 
37.  Psaty BM, O’Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, Rotter JI, 687 
Uitterlinden AG, Harris TB, Witteman JCM, Boerwinkle E. Cohorts for Heart and 688 
Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of 689 
prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ 690 
Cardiovasc Genet 2: 73–80, 2009. 691 
38.  Qiang X, Yang W-L, Wu R, Zhou M, Jacob A, Dong W, Kuncewitch M, Ji Y, Yang 692 
H, Wang H, Fujita J, Nicastro J, Coppa GF, Tracey KJ, Wang P. Cold-inducible 693 
RNA-binding protein (CIRP) triggers inflammatory responses in hemorrhagic shock 694 
and sepsis. Nat Med 19: 1489–95, 2013. 695 
39.  R Core Team. R: A language and environment for statistical computing. R Foundation 696 
for Statistical Computing: 2014. 697 
40.  Rantanen T. Muscle strength, disability and mortality. Scand J Med Sci Sports 13: 3–698 
8, 2003. 699 
41.  Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: integrating 700 
information about genes, proteins and diseases. Trends Genet 13: 163, 1997. 701 
42.  Ruffell D, Mourkioti F, Gambardella A, Kirstetter P, Lopez RG, Rosenthal N, 702 
Nerlov C. A CREB-C/EBPbeta cascade induces M2 macrophage-specific gene 703 
expression and promotes muscle injury repair. Proc Natl Acad Sci U S A 106: 17475–704 
80, 2009. 705 
43.  Samson MM, Meeuwsen IB, Crowe A, Dessens JA, Duursma SA, Verhaar HJ. 706 
Relationships between physical performance measures, age, height and body weight 707 
in healthy adults. Age Ageing 29: 235–242, 2000. 708 
44.  Schaap LA, Pluijm SMF, Deeg DJH, Visser M. Inflammatory markers and loss of 709 
muscle mass (sarcopenia) and strength. Am J Med 119: 526.e9–17, 2006. 710 
45.  Schurmann C, Heim K, Schillert A, Blankenberg S, Carstensen M, Dörr M, 711 
Endlich K, Felix SB, Gieger C, Grallert H, Herder C, Hoffmann W, Homuth G, Illig 712 
T, Kruppa J, Meitinger T, Müller C, Nauck M, Peters A, Rettig R, Roden M, 713 
Strauch K, Völker U, Völzke H, Wahl S, Wallaschofski H, Wild PS, Zeller T, 714 
Teumer A, Prokisch H, Ziegler A. Analyzing illumina gene expression microarray 715 
data from different tissues: methodological aspects of data analysis in the metaxpress 716 
consortium. PLoS One 7: e50938, 2012. 717 
46.  Sharples AP, Al-Shanti N, Hughes DC, Lewis MP, Stewart CE. The role of insulin-718 
like-growth factor binding protein 2 (IGFBP2) and phosphatase and tensin homologue 719 
(PTEN) in the regulation of myoblast differentiation and hypertrophy. Growth Horm 720 
IGF Res 23: 53–61, 2013. 721 
47.  Shiratori AP, Iop R da R, Júnior NGB, Domenech SC, Gevaerd M da S. Evaluation 722 
protocols of hand grip strength in individuals with rheumatoid arthritis: A systematic 723 
review. Rev. Bras. Reumatol. 54: 140–147, 2014. 724 
48.  Sinha M, Jang YC, Oh J, Khong D, Wu EY, Manohar R, Miller C, Regalado SG, 725 
Loffredo FS, Pancoast JR, Hirshman MF, Lebowitz J, Shadrach JL, Cerletti M, 726 
Kim M-J, Serwold T, Goodyear LJ, Rosner B, Lee RT, Wagers AJ. Restoring 727 
systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. 728 
Science 344: 649–52, 2014. 729 
 
 
33 
 
49.  Siritantikorn A, Johansson K, Ahlen K, Rinaldi R, Suthiphongchai T, Wilairat P, 730 
Morgenstern R. Protection of cells from oxidative stress by microsomal glutathione 731 
transferase 1. Biochem Biophys Res Commun 355: 592–6, 2007. 732 
50.  Thiery J, Keefe D, Boulant S, Boucrot E, Walch M, Martinvalet D, Goping IS, 733 
Bleackley RC, Kirchhausen T, Lieberman J. Perforin pores in the endosomal 734 
membrane trigger the release of endocytosed granzyme B into the cytosol of target 735 
cells. Nat Immunol 12: 770–7, 2011. 736 
51.  Visser M, Deeg DJ, Lips P, Harris TB, Bouter LM. Skeletal muscle mass and 737 
muscle strength in relation to lower-extremity performance in older men and women. J 738 
Am Geriatr Soc 48: 381–386, 2000. 739 
52.  Völzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, Aumann N, Lau 740 
K, Piontek M, Born G, Havemann C, Ittermann T, Schipf S, Haring R, Baumeister 741 
SE, Wallaschofski H, Nauck M, Frick S, Arnold A, Jünger M, Mayerle J, Kraft M, 742 
Lerch MM, Dörr M, Reffelmann T, Empen K, Felix SB, Obst A, Koch B, Gläser S, 743 
Ewert R, Fietze I, Penzel T, Dören M, Rathmann W, Haerting J, Hannemann M, 744 
Röpcke J, Schminke U, Jürgens C, Tost F, Rettig R, Kors JA, Ungerer S, 745 
Hegenscheid K, Kühn J-PJ, Kühn J-PJ, Hosten N, Puls R, Henke J, Gloger O, 746 
Teumer A, Homuth G, Völker U, Schwahn C, Holtfreter B, Polzer I, Kohlmann T, 747 
Grabe HJ, Rosskopf D, Kroemer HK, Kocher T, Biffar R, John U, Hoffmann W. 748 
Cohort profile: the study of health in Pomerania. Int J Epidemiol 40: 294–307, 2011. 749 
53.  Wang J, Duncan D, Shi Z, Zhang B. WEB-based GEne SeT AnaLysis Toolkit 750 
(WebGestalt): update 2013. Nucleic Acids Res 41: W77–83, 2013. 751 
54.  Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of 752 
genomewide association scans. Bioinformatics 26: 2190–1, 2010. 753 
55.  Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie 754 
J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent 755 
stem cell lines derived from human somatic cells. Science 318: 1917–20, 2007. 756 
56.  Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene 757 
sets in various biological contexts. Nucleic Acids Res 33: W741–8, 2005.  758 
  759 
 
 
34 
 
Table 1 | Characteristics of the study cohorts 760 
 761 
Meta-analysis cohorts Additional cohort ∞ 
Variables FHS Gen 2 * FHS Gen 3 * InCHIANTI ~ RS3 ~ SHIP ~   NESDA 
N 2,421 3,155 667 556 982 1,989 
N >= 60 years (%) 1,319 (54%) 48 (1%) 547 (81%) 264 (45%) 268 (27%) 158 (8%) 
Sex (male), n (%) 1,095 (45%) 1,470 (47%) 311 (46%) 272 (46%) 435 (44%) 1,328 (67%) 
Age (yrs), mean±SD 66 ± 8.9 46 ± 8.8 72 ± 15 60 ± 7.9 50 ± 14 42 ± 13 
Age (yrs), min:max 40 : 90 24 : 78 30 : 104 46 : 89 20 : 81 18 : 65 
WBC-counts yes ɫ yes  yes yes yes no 
Hand-grip strength 
Mean ± SD (Kg) 31 ± 12 38 ± 12 29 ± 12 25 ± 9.4 38 ± 12 38 ± 12 
Min : max (Kg) 1 : 76 5 : 84 3 : 76 2 : 55 11 : 73 10 : 90 
Microarray platform 
Affymetrix 
GeneChip 
Human 
Exon 1.0 ST 
Affymetrix 
GeneChip 
Human 
Exon 1.0 ST 
Illumina 
HumanHT-
12 v3 
BeadChip 
Illumina 
HumanHT-
12 v4 
BeadChip 
Illumina 
HumanHT-
12 v3 
BeadChip 
 
Affymetrix Human 
Genome U219 Array 
                
FHS=Framingham Heart Study; RS3=Rotterdam Study 3; SHIP=Study of Health in Pomerania; NESDA=Netherlands Study of 
Depression and Anxiety; SD=standard deviation; WBC=white blood cell 
* FHS cohorts analyzed together prior to overall meta-analysis 
~ Illumina-based cohorts analyzed together prior to overall meta-analysis 
∞ cohort not included in meta-analysis due to data missing from analysis protocol 
ɫ cell counts imputed in this dataset; see methods 
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Table 2 | Top 20 unique genes associated with muscle strength in the meta-analysis of all participants, with robust replication in Illumina 762 
 763 
Meta-analysis p-values 
Zscore p-value BH p-value FHS Illumina Gene EntrezID Name 
-5.67 1.5x10-8 2.0x10-4 3.9x10-7 9.9x10-3 ALAS2 212 aminolevulinate, delta-, synthase 2 
5.37 7.8x10-8 3.1x10-4 4.3x10-7 4.0x10-2 HEATR5A 25938 HEAT repeat containing 5A 
-5.28 1.3x10-7 3.9x10-4 2.7x10-5 1.2x10-3 PNP 4860 purine nucleoside phosphorylase 
-5.17 2.4x10-7 4.7x10-4 1.1x10-6 5.0x10-2 STOM 2040 stomatin 
5.14 2.8x10-7 4.7x10-4 7.9x10-6 1.1x10-2 RPS6KA5 9252 ribosomal protein S6 kinase, 90kDa, polypeptide 5 
-5.09 3.7x10-7 5.8x10-4 5.4x10-5 1.8x10-3 MBNL3 55796 Muscleblind-Like Splicing Regulator 3 
-5.07 3.9x10-7 5.8x10-4 2.3x10-6 4.4x10-2 RAD23A 5886 RAD23 homolog A (S. cerevisiae) 
5.02 5.1x10-7 6.8x10-4 7.7x10-5 1.7x10-3 HNRNPA0 10949 heterogeneous nuclear ribonucleoprotein A0 
-4.90 9.5x10-7 1.1x10-3 2.0x10-5 1.5x10-2 GID4 79018 GID Complex Subunit 4 
-4.88 1.1x10-6 1.1x10-3 9.3x10-6 3.4x10-2 TFDP1 7027 transcription factor Dp-1 
4.80 1.6x10-6 1.4x10-3 9.9x10-6 4.7x10-2 ARRDC3 57561 arrestin domain containing 3 
-4.77 1.7x10-6 1.5x10-3 1.8x10-5 3.3x10-2 RIOK3 8780 RIO kinase 3 
-4.71 2.5x10-6 1.8x10-3 1.9x10-5 4.1x10-2 NTAN1 123803 N-terminal asparagine amidase 
4.66 3.1x10-6 2.2x10-3 8.1x10-4 6.0x10-4 PDE4D 5144 phosphodiesterase 4D, cAMP-specific 
-4.62 3.8x10-6 2.4x10-3 1.1x10-4 1.2x10-2 RGCC 28984 Regulator Of Cell Cycle 
4.61 4.1x10-6 2.5x10-3 9.6x10-5 1.4x10-2 POLR2B 5431 polymerase (RNA) II (DNA directed) polypeptide B 
-4.59 4.4x10-6 2.5x10-3 6.1x10-5 2.4x10-2 EIF1B 10289 eukaryotic translation initiation factor 1B 
4.57 4.8x10-6 2.7x10-3 5.4x10-4 2.0x10-3 CIRBP 1153 cold inducible RNA binding protein 
-4.57 4.8x10-6 2.7x10-3 6.2x10-5 2.7x10-2 ASGR2 433 asialoglycoprotein receptor 2 
-4.55 5.3x10-6 2.9x10-3 3.8x10-5 4.5x10-2 CA1 759 carbonic anhydrase I 
BH=Benjamini-Hochberg. Ordered by meta-analysis p-value. Showing top 20 results with nominal 'replication' (p<0.05) in Illumina. 
Duplicate gene entries excluded. Full table in Supplementary Table 1.  
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 764 
Table 3 | Thirteen genes associated with muscle strength in age or gender specific subset analyses 765 
 766 
Subset Meta-analysis of subset p-values 
Group N Zscore P-value BH P-value FHS Illumina Gene Name 
Younger & Male 5379 -4.879 1.1 x10-6 9.5 x10-3 2.4 x10-6 1.3 x10-1 ASAP1 ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 
Younger 5379 4.495 6.9 x10-6 2.5 x10-2 7.5 x10-5 3.3 x10-1 PKN2 protein kinase N2 
Younger 5379 -4.426 9.6 x10-6 2.5 x10-2 2.9 x10-5 6.1 x10-1 RNF175 ring finger protein 175 
Younger 5379 -4.407 1.1 x10-5 2.5 x10-2 3.3 x10-5 2.4 x10-1 TMED5 transmembrane emp24 protein transport domain containing 5 
Younger 5379 4.235 2.3 x10-5 3.5 x10-2 4.2 x10-5 4.7 x10-1 ZFYVE27 zinc finger, FYVE domain containing 27 
Younger & Male 5379 -4.217 2.5 x10-5 3.5 x10-2 3.4 x10-3 2.5 x10-3 GID8 GID complex subunit 8 
Younger 5379 -4 6.3 x10-5 4.2 x10-2 1.7 x10-4 1.2 x10-2 PIK3R2 phosphoinositide-3-kinase, regulatory subunit 2 
Younger 5379 -3.961 7.5 x10-5 4.2 x10-2 7.3 x10-6 3.3 x10-1 PDK4 pyruvate dehydrogenase kinase, isozyme 4 
Younger 5379 -3.961 7.5 x10-5 4.2 x10-2 2.0 x10-6 6.7 x10-1 CTNNAL1 catenin (cadherin-associated protein), alpha-like 1 
Younger 5379 -3.937 8.3 x10-5 4.4 x10-2 7.6 x10-5 1.2 x10-1 COQ9 coenzyme Q9 
Male 3557 4.565 5.0 x10-6 1.9 x10-2 1.2 x10-5 1.1 x10-1 RAC1 ras-related C3 botulinum toxin substrate 1 
Male 3557 4.041 5.3 x10-5 4.3 x10-2 8.0 x10-5 1.9 x10-1 NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa ... 
Female 4224 -4.907 9.3 x10-7 2.5 x10-2 8.0 x10-4 1.1 x10-4 DEFA4 defensin, alpha 4, corticostatin 
BH=Benjamini-Hochberg. Some genes were identified in in multiple groups; for these genes the statistics for the larger group are given; in all cases direction of 
association is the same. Ordered by subset, then P-value. 
 767 
  768 
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Table 4 | Top 20 probes in the FHS analysis that did not map to a corresponding Illumina probe, ordered by p-value 769 
 770 
Estimate P-value BH P-value Chr Start Gene Name 
-0.0037 1.76x10-6 1.49x10-3 1 144989319 
-0.0028 4.89x10-6 2.88x10-3 9 37800563 DCAF10 DDB1 and CUL4 associated factor 10 
0.0031 8.57x10-6 4.12x10-3 1 150522766 ADAMTSL4 ADAMTS(a disintegrin and metalloproteinase with thrombospondin motifs)-like 4 
0.0038 9.29x10-6 4.15x10-3 16 89980135 
0.0040 1.95x10-5 5.97x10-3 2 162412847 SLC4A10 solute carrier family 4, sodium bicarbonate transporter, member 10 
0.0029 3.24x10-5 7.74x10-3 16 9186734 
0.0031 3.93x10-5 8.51x10-3 1 44440179 ATP6V0B ATPase, H+ transporting, lysosomal 21kDa, V0 subunit b 
-0.0027 4.10x10-5 8.64x10-3 3 63819562 THOC7 THO complex 7 homolog (Drosophila) 
0.0032 5.38x10-5 9.81x10-3 20 3898284 
0.0019 1.49x10-4 1.70x10-2 20 1316212 
0.0018 1.89x10-4 1.91x10-2 3 128628719 ACAD9 | KIAA1257 acyl-CoA dehydrogenase family, member 9 | KIAA1257 
-0.0017 2.21x10-4 2.08x10-2 1 8021733 PARK7 parkinson protein 7 
0.0036 3.18x10-4 2.69x10-2 12 57809458 
0.0010 3.20x10-4 2.70x10-2 1 153901987 DENND4B DENN/MADD domain containing 4B 
-0.0019 3.56x10-4 2.87x10-2 3 10157370 BRK1 BRICK1, SCAR/WAVE actin-nucleating complex subunit 
-0.0028 3.84x10-4 2.97x10-2 2 95517671 TEKT4 tektin 4 
-0.0014 3.95x10-4 3.03x10-2 1 247937996 OR9H1P olfactory receptor, family 9, subfamily H, member 1 pseudogene 
0.0018 6.01x10-4 3.89x10-2 9 124042152 GSN-AS1 GSN(gelsolin) antisense RNA 1 
0.0028 6.41x10-4 4.03x10-2 6 20451305 
-0.0021 6.90x10-4 4.19x10-2 12 8024178 NANOGP1 | NANOG Nanog homeobox pseudogene 1 | Nanog homeobox 
BH=Benjamini-Hochberg. Blank gene symbols were not annotated to a specific gene. Table continued in Supplementary Table 9. Ordered by P-value. Not all probes map 
to gene ID’s. 
 771 
 772 
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Table 5 | Ten biological processes were enriched in the genes associated with muscle strength in the analysis of all participants 773 
 774 
Biological Process C O rawP adjP Top Genes 
hemoglobin metabolic process (GO:0020027) 14 5 3.2x10-7 0.0004 ALAS2, AHSP, FECH, EIF2AK2, EPB42 
hemoglobin biosynthetic process (GO:0042541) 9 3 1.0x10-4 0.0139 ALAS2, FECH, EIF2AK2 
innate immune response (GO:0045087) 539 18 3.8x10-5 0.0139 RPS6KA5, IFI27, TLR5, DUSP3, FCGR1B 
negative regulation of protein metabolic process (GO:0051248) 460 16 6.5x10-5 0.0139 IGF2BP2, CIRBP, BANP, GCLC, DUSP3 
posttranscriptional regulation of gene expression (GO:0010608) 371 14 8.0x10-5 0.0139 HNRNPA0, IGF2BP2, EIF1B, CIRBP, ASGR2 
response to arsenic-containing substance (GO:0046685) 20 4 6.5x10-5 0.0139 GCLC, GSTO1, FECH, DDX3X 
regulation of translational initiation by eIF2a ... (GO:0010998) 2 2 1.0x10-4 0.0139 FECH, EIF2AK2 
regulation of eIF2 alpha phosphorylation by heme (GO:0010999) 2 2 1.0x10-4 0.0139 FECH, EIF2AK2 
response to stress (GO:0006950) 2952 55 4.7x10-5 0.0139 ALAS2, RPS6KA5, RAD23A, HNRNPA0, UBQLN1 
protoporphyrinogen IX metabolic process (GO:0046501) 11 3 2.0x10-4 0.0167 FECH, ALAS2, EIF2AK2 
 775 
C=number of reference genes in the category; O=number of genes in the gene set and also in the category; rawP=p value from hypergeometric 776 
test; adjP=p value adjusted by the multiple test adjustment (Benjamini-Hochberg); Top Genes=top five genes from pathway based on meta-777 
analysis P-value 778 
  779 
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Figure Legend 780 
 781 
Figure 1. Gene transcripts associated with muscle strength in all participants 782 
 783 
A) Compares the individual meta-analyses performed in the Illumina-cohorts and the FHS 784 
separately. The dark grey points represent gene transcripts significantly associated with 785 
muscle strength (FDR<0.05). The light grey points were not significant in this analysis. The 786 
unfilled grey points were excluded due to significant heterogeneity (Cochran's Q-test p < 0.05 787 
(54)). The solid grey line shows the trend across all the genes.  788 
B) Shows the meta-analysis results by Manhattan plot. The dashed line indicates those 789 
probes significantly associated with grip strength after Benjamini-Hochberg correction, the 790 
solid line shows those significant after Bonferroni correction, for comparison. 791 
  792 
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Additional Files 793 
Table.Supplementary.1.Meta-analysis-results.all-participants.xlsx 794 
• Microsoft Excel file (.xlsx) 795 
• Significant meta-analysis results in analysis of all participants 796 
 797 
Table.Supplementary.2.Meta-analysis-results.younger-participants.xlsx 798 
• Microsoft Excel file (.xlsx) 799 
• Significant meta-analysis results in analysis of younger participants only 800 
 801 
Table.Supplementary.3.Meta-analysis-results.male-participants.xlsx 802 
• Microsoft Excel file (.xlsx) 803 
• Significant meta-analysis results in analysis of male participants only 804 
 805 
Table.Supplementary.4.Meta-analysis-results.female-participants.xlsx 806 
• Microsoft Excel file (.xlsx) 807 
• Significant meta-analysis results in analysis of female participants only 808 
 809 
Table.Supplementary.5.Additional-information-for-genes.xlsx 810 
• Microsoft Excel file (.xlsx) 811 
• Additional information for prominent genes 812 
• Tables 2 and 3 contain genes of particular robustness or interest that are here 813 
described in further detail 814 
 815 
Table.Supplementary.6.FHS-only-analysis-results.all-participants.xlsx 816 
• Microsoft Excel file (.xlsx) 817 
• Significant results for genes available in the FHS data only (all participants) 818 
 819 
Table.Supplementary.7.FHS-only-analysis-results.younger-participants.xlsx 820 
• Microsoft Excel file (.xlsx) 821 
• Significant results for genes available in the FHS data only (younger participants) 822 
 823 
Table.Supplementary.8.FHS-only-analysis-results.male-participants.xlsx 824 
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• Microsoft Excel file (.xlsx) 825 
• Significant results for genes available in the FHS data only (male participants) 826 
 827 
Table.Supplementary.9.WebGestalt-Gene-Ontology-pathway-analysis.xlsx 828 
• Microsoft Excel file (.xlsx) 829 
• Significantly enriched Gene Ontology terms in the 208 genes 830 
• WebGestalt-determined Gene Ontology terms that are significantly enriched in the 831 
208 genes found to be associated with muscle strength in the meta-analysis of all 832 
participants 833 
 834 
Table.Supplementary.10.WebGestalt-Phenotype-Ontology-pathway-analysis.xlsx 835 
• Microsoft Excel file (.xlsx) 836 
• Significantly enriched Human Phenotype Ontology terms in the 208 genes 837 
• WebGestalt-determined Human Phenotype Ontology terms that are significantly 838 
enriched in the 208 genes found to be associated with muscle strength in the meta-839 
analysis of all participants 840 
 841 
Table.Supplementary.11.network_GO-enrichment_results.xlsx 842 
• Microsoft Excel file (.xlsx) 843 
• Ontology enrichment results for the four clusters described in the network-analysis 844 
results section 845 
• For each network of co-expressed genes with >=10 genes in the network (n=4) we 846 
present the results of a Gene Ontology enrichment analysis. 847 
 848 
Table.Supplementary.12.Literature-search.xlsx 849 
• Microsoft Excel file (.xlsx) 850 
• Systematic search of the literature for 221 genes associated with muscle 851 
• For each of the 221 genes found in this analysis to be associated with muscle 852 
strength, GeneCards and PubMed were used to identify published research articles 853 
that contain both the gene ID (including part synonyms) and the word “muscle” 854 
 855 

